250 related articles for article (PubMed ID: 1700348)
1. Maternal serum screening for aneuploid pregnancy by alpha-fetoprotein, hCG, and unconjugated estriol.
Heyl PS; Miller W; Canick JA
Obstet Gynecol; 1990 Dec; 76(6):1025-31. PubMed ID: 1700348
[TBL] [Abstract][Full Text] [Related]
2. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
[TBL] [Abstract][Full Text] [Related]
3. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
[TBL] [Abstract][Full Text] [Related]
4. A retrospective evaluation of maternal serum screening for the detection of fetal aneuploidy.
Suzumori K; Tanemura M; Murakami I; Okada S; Natori M; Tanaka M; Takagi T; Sato A
Prenat Diagn; 1997 Sep; 17(9):861-6. PubMed ID: 9316131
[TBL] [Abstract][Full Text] [Related]
5. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
[TBL] [Abstract][Full Text] [Related]
6. Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: impact on Down syndrome screening.
Palomaki GE; Knight GJ; Haddow JE; Canick JA; Wald NJ; Kennard A
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):675-8. PubMed ID: 7682315
[TBL] [Abstract][Full Text] [Related]
7. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
Dick PT
CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
[TBL] [Abstract][Full Text] [Related]
8. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
[TBL] [Abstract][Full Text] [Related]
9. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies.
Benn PA
Prenat Diagn; 1998 Apr; 18(4):319-24. PubMed ID: 9602476
[TBL] [Abstract][Full Text] [Related]
10. Serum markers for Down's syndrome in relation to number of previous births and maternal age.
Wald NJ; Watt HC
Prenat Diagn; 1996 Aug; 16(8):699-703. PubMed ID: 8878278
[TBL] [Abstract][Full Text] [Related]
11. The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome.
Christiansen M; Høgdall EV; Larsen SO; Høgdall C
Prenat Diagn; 2002 May; 22(5):385-7. PubMed ID: 12001192
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of trisomy 21 risk by serial determination of chorionic gonadotrophin hormone and alpha-fetoprotein: results of a national pilot study].
Aymé S; Aurran Y; Chabal F; Gombert A; Loundou H; Montfort C; Sollier M; Silvestri A
Contracept Fertil Sex; 1993 Feb; 21(2):133-43. PubMed ID: 7524931
[TBL] [Abstract][Full Text] [Related]
13. Dependence of maternal serum [AFP]/[hCG] median ratios on age of gestation: comparison of trisomy 21 to euploid pregnancies.
Marcus-Braun N; Birk O; Manor E; Segal D; Harari G; Toma I; Shalev S; Borochowitz ZU; Yaron Y; Sharony R; Itzhaky D; Shtoyerman R; Appelman Z; Braun G
Prenat Diagn; 2009 Dec; 29(12):1130-4. PubMed ID: 19777489
[TBL] [Abstract][Full Text] [Related]
14. Triploidy identified through second-trimester serum screening.
Huang T; Alberman E; Wald N; Summers AM
Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
[TBL] [Abstract][Full Text] [Related]
15. [Prenatal maternal blood screening for the detection of fetal chromosomal abnormalities: clinical importance of the rate of false positives].
Alvarez-Nava F; Soto M; Padrón T; Morales A; Villalobos D; Rojas de Atencio A; Prieto M; Martínez MC
Invest Clin; 2003 Sep; 44(3):195-207. PubMed ID: 14552058
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
[TBL] [Abstract][Full Text] [Related]
17. [Serum screening of pregnant women reveals Down syndrome. Analysis of biochemical markers for earlier detection].
Christiansen M; Larsen SO; Nørgaard-Pedersen B
Lakartidningen; 1997 Dec; 94(51-52):4898-902. PubMed ID: 9454010
[TBL] [Abstract][Full Text] [Related]
18. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
[TBL] [Abstract][Full Text] [Related]
19. Maternal serum screening.
Carroll JC
Can Fam Physician; 1994 Oct; 40():1756-64. PubMed ID: 7524838
[TBL] [Abstract][Full Text] [Related]
20. [The prenatal diagnosis of Down's syndrome based on the biochemical screening of maternal serum markers].
Arbuzova SB; Nikolenko MI; Khlevnaia LA; Fedotova OO; Solov'eva VD; Malova SA
Tsitol Genet; 1998; 32(1):66-71. PubMed ID: 9695254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
